Antianginal Therapy for Stable Ischemic Heart Disease

Heart Disease and Stroke Statistics—2016 Update

(2015) Dariush Mozaffarian et al.   CIRCULATION

 -Blockers and Cardiovascular Events in Patients With and Without Myocardial Infarction: Post Hoc Analysis From the CHARISMA Trial

(2014) S. Bangalore et al.  

Ivabradine in Stable Coronary Artery Disease without Clinical Heart Failure

(2014) Kim Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selective and Specific Inhibition of I f with Ivabradine for the Treatment of Coronary Artery Disease or Heart Failure

(2013) Prakash Deedwania   DRUGS

2013 ESC guidelines on the management of stable coronary artery disease

(2013)   EUROPEAN HEART JOURNAL

Symptoms of angina pectoris increase the probability of disability pension and premature exit from the workforce even in the absence of obstructive coronary artery disease

(2013) L. Jespersen et al.   EUROPEAN HEART JOURNAL

Evaluation of Ranolazine in Patients With Type 2 Diabetes Mellitus and Chronic Stable Angina

(2013) Mikhail Kosiborod et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease

(2012) Stephan D. Fihn et al.   CIRCULATION

Nitrates as an Integral Part of Optimal Medical Therapy and Cardiac Rehabilitation for Stable Angina: Review of Current Concepts and Therapeutics

(2012) William E. Boden et al.   CLINICAL CARDIOLOGY

β-Blocker Use and Clinical Outcomes in Stable Outpatients With and Without Coronary Artery Disease

(2012) Sripal Bangalore et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Obstructive Coronary Atherosclerosis and Ischemic Heart Disease: An Elusive Link!

(2012) Mario Marzilli et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Forecasting the Future of Cardiovascular Disease in the United States

(2011) Paul A. Heidenreich et al.   CIRCULATION

Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events

(2011) L. Jespersen et al.   EUROPEAN HEART JOURNAL

Ranolazine and Its Anti-Ischemic Effects

(2010) William E. Boden   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Low Diagnostic Yield of Elective Coronary Angiography

(2010) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluation of the Glycometabolic Effects of Ranolazine in Patients With and Without Diabetes Mellitus in the MERLIN-TIMI 36 Randomized Controlled Trial

(2009) David A. Morrow et al.   CIRCULATION

Persistent Chest Pain and No Obstructive Coronary Artery Disease

(2009) Anita Phan   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Efficacy of Ranolazine in Patients With Chronic Angina

(2009) Sean R. Wilson et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Effect of Sirolimus on Left Ventricular Hypertrophy in Kidney Transplant Recipients: A 1-Year Nonrandomized Controlled Trial

(2008) Ernesto Paoletti et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Sirolimus affects cardiomyocytes to reduce left ventricular mass in heart transplant recipients

(2008) S. S. Kushwaha et al.   EUROPEAN HEART JOURNAL

Ranolazine Inhibits An Oxidative Stress-induced Increase in Myocyte Sodium and Calcium Loading During Simulated-demand Ischemia

(2008) Xiu Q Zhang et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial

(2008) Kim Fox et al.   LANCET

Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR−/− mice despite severe hypercholesterolemia

(2007) Marc A. Mueller et al.   ATHEROSCLEROSIS